Leukocyte tyrosine kinase (LTK) is a receptor-type protein tyrosine kinase belonging to the insulin receptor superfamily. To elucidate its biological role, we generated transgenic mice expressing LTK under the control of cytomegarovirus enhancer and b-actin promoter. The transgenic mice exhibited growth retardation and most of the transgenic mice died within several months after birth. Interestingly, although LTK was expressed in several major organs, the activation (tyrosine-phosphorylation, kinase activity, and multimerization) of LTK was observed selectively in the heart, where LTK was localized on intracellular membrane, presumably on endoplasmic reticulum. Echocardiography showed that the transgenic heart underwent severe concentric hypertrophy, which resulted in reduced cardiac output, low blood pressure, and increased heart rate. Histological examination of the heart exhibited focal degeneration of cardiomyocytes. These histological changes were considered to be due to apoptosis, based on the ®nding that the sarcolemmas of the degenerative cardiomyocytes were well preserved. In addition, expression of fetal genes, such as atrial natriuretic peptide and skeletal a-actin, was markedly induced in the transgenic heart. These results indicate that a certain tissue-speci®c mechanism of activating LTK exists in the heart and that the activated LTK resulted in cardiac hypertrophy, cardiomyocyte degeneration and gene reprogramming. These ®ndings will provide novel insights into the activating mechanism and biological role of LTK in vivo.
Introduction
Protein tyrosine kinases are implicated in various biological processes, such as cell growth and differentiation. Leukocyte tyrosine kinase (LTK) is a receptor-type protein tyrosine kinase, initially cloned from mouse (Ben-Neriah and Bauskin, 1988) and subsequently from human (Maru et al., 1990) . Although the kinase domain of LTK had a similarity to that of insulin receptor, the overall structure was considered to be unique among receptor-type proteintyrosine kinases on the basis of the ®nding of having only 8 amino acids in the extracellular domain (BenNeriah and Bauskin, 1988; Maru et al., 1990) . However, recent studies have revealed that murine and human LTKs have larger extracellular domains than initially reported (Bernards and de la Monte, 1990; Hasse et al., 1991; Krolewski and Dalla-Farvera, 1991; Snijders et al., 1993; Toyoshima et al., 1993) . In the mouse, CTG and ATG codons present several hundred basepairs upstream of the initially proposed ATG have been shown to serve as translation initiation codons (Bernards and de la Monte, 1990; Hasse et al., 1991; Snijders et al., 1993) . Subsequently, we and others have shown that human LTK encodes a conventional receptor-type protein-tyrosine kinase consisting of a large extracellular region including the signal sequence, a transmembrane region, and a cytoplasmic region containing the kinase domain (Krolewski and Dalla-Farvera, 1991; . These results suggest that LTK may function as a receptor of unknown ligand(s) and transduce signal(s) through its kinase activity in response to the ligand binding. However, since the extracellular region of LTK has no signi®cant homology to known proteins except that of ALK (Morris et al., 1997) and no speci®c ligand(s) for LTK has been identi®ed, the function of LTK has remained essentially unknown. Recently, we have made several dierent approaches to clarify the function of LTK.
We raised monoclonal antibodies against human LTK . With use of the antibodies, LTK was detected as a protein of approximately 100 Kd with kinase activity in human placenta and hematopoietic cell lines expressing ltk mRNA . In addition, when overexpressed in Cos-1 cells, LTK was found to be tyrosine-phosphorylated and was associated with several Src homology (SH) 2-containing proteins, such as the p85 subunit of phosphatidylinositol 3 kinase (PI3 kinase), phospholipase C-g (PLC-g), and p21 ras GTPase activating protein (GAP), and serine/threonine kinase, Raf-1, in its kinase activity-dependent manner (Kozutsumi et al., 1994) . Subsequently, we created a chimeric molecule, in which the extracellular region of LTK was replaced by that of epidermal growth factor (EGF) receptor (named EGFR-LTK) (Ueno et al., 1995) . When the fusion protein was stably expressed in human embryonic kidney ®broblasts, EGF stimulation rendered a proliferative advantage to the EGFR-LTKexpressing cells in comparison to their parental cells (Ueno et al., 1995 (Ueno et al., , 1996 . These results suggest that LTK may evoke growth signals in the activated state like other many receptor-type protein-tyrosine kinases.
These studies have provided us with insights into the function of LTK. However, since they were carried out using LTK transiently expressed in Cos-1 cells or using EGFR-LTK chimeric molecule expressed in immortalized cells, the in vivo role of LTK cannot be fully understood. To address this issue, we generated and analysed transgenic mice expressing LTK.
Results
The transgenic mice exhibited growth retardation and high mortality rate
We generated transgenic mice expressing LTK under the control of cytomegarovirus enhancer and b-actin promoter. The schematic structure of the transgene is shown in Figure 1 . Microinjection resulted in generation of three founder mice carrying 1 ± 3 copies of the transgene (data not shown). All the founder mice transmitted the transgene stably to the progeny and three independent lines were established (designated as 3-5, 3-11, and 4-17) . Although the transgenic ospring showed no apparent abnormalities soon after birth, they exhibited retarded growth and died in young age. The changes in body weights of transgenic mice and non-transgenic littermates are shown in Figure 2a . As shown in Figure 2a , gain in the body weight of the transgenic mice was signi®cantly less than that of their non-transgenic littermates. The survival curves of the transgenic mice and non-transgenic littermates are shown in Figure 2b . As shown in Figure 2b , almost all the transgenic mice died within 100 days after birth, whereas no non-transgenic littermates died within this period. These results indicated that the expression of LTK induced growth retardation and high mortality rate in the transgenic mice.
The LTK transgene product was activated selectively in the heart
To investigate the expression and tyrosine-phosphorylation of the LTK transgene product, proteins extracted from tissues of transgenic mice and nontransgenic littermates were incubated with an antihuman LTK monoclonal antibody, 1D31, and the immunoprecipitated proteins were blotted with 1D31 or anti-phosphotyrosine monoclonal antibody, 4G10.
In animal line 3-5, the LTK transgene product was expressed highly in the heart and weakly in the brain (indicated by an arrow in the upper panel of Figure  3a) , with tyrosine-phosphorylation of the protein being observed limited to the heart (indicated by an arrow in the lower panel of Figure 3a ). In line 3-11, the expression and tyrosine phosphorylation patterns of LTK were similar to those observed in line 3-5 (data not shown). In line 4-17, in contrast to other two lines, the expression of the LTK transgene product was detected in several major organs, such as brain, lung, heart, and spleen and high expression levels were observed in the brain and heart (indicated by an arrow in the upper panel of Figure 3b ). In spite of this wide expression pattern, however, tyrosine-phosphorylation of LTK was detected exclusively in the heart (indicated by an arrow in the lower panel of Figure 3b ). We then examined the kinase activity of the expressed LTK transgene product by the in vitro kinase assays. Since the results were essentially similar among the three transgenic lines, that of line 4-17, which expressed the LTK transgene product most widely among the lines (see the upper panels of Figure 3a and b), is presented. As shown in Figure 3c , the kinase activity of LTK was detected only in the heart, where LTK was selectively tyrosine-phosphorylated (see the lower panels of Figure  3a and b). We further examined whether the phosphorylated LTK in the heart formed multimers, since a previous study showed that the kinase activity of LTK was directly linked to multimerization of the protein (Braskin et al., 1991) . The in vitro kinase assay products of the hearts were electrophoresed under reducing and non-reducing conditions. As shown in Figure 3d , under the reducing condition, approximately 100 Kd phosphorylated band was observed as expected (indicated by an arrow), whereas under the nonreducing condition, additional phosphorylated bands of approximately 200 Kd and 300 Kd were detected (indicated by arrowheads), which correspond to the molecular weights of the dimerized and trimerized LTK, respectively. These results demonstrated that although the LTK transgene product was expressed in several major organs, the activation (tyrosine-phos- , and posterior wall (PW) of a transgenic heart (Tg) and a non-transgenic heart (C) (30 weeks of age) are indicated phorylation, kinase activity, and multimerization) of LTK occurred selectively in the heart. The LTK transgene product was expressed as a receptor protein and was localized on intracellular membrane, presumably on endoplasmic reticulum
The transgene was created using the longest form of human ltk cDNA, which encodes a conventional receptor-type tyrosine kinase having a signal sequence and a transmembrane region . To con®rm that the LTK transgene product was expressed as a receptor protein and to examine its localization within the cells, the subcellular fractionation and immuno¯uorescent staining were performed. The heart, where the LTK transgene product was abundantly expressed (Figure 3a and b) , was used as a specimen. For subcellular fractionation, proteins in the transgenic heart were separated into cytosolic and membranous fractions by two step centrifugation and the proteins of each fraction were subjected to immunoprecipitation/Western blot analysis with 1D31. As shown in Figure 4a , LTK was detected speci®cally in the membranous fraction, providing evidence that the LTK transgene product was expressed as a membrane protein. To further examine its localization, the transgenic heart was immunouorescently stained with 1D31 and staining with antib-Catenin antibody was done to identify cell surface membrane (Ozawa et al., 1990) . As shown in Figure  4b , staining with 1D31 showed signals with continuous and reticular patterns within the cells, in contrast that staining with anti-b-Catenin antibody showed signals along the cell surface membranes. This result, together with the result obtained by the subcellular fractionation, indicated that the LTK transgene product was expressed as a receptor protein and was located on intracellular membrane, presumably on endoplasmic reticulum, as shown in previous papers (Braskin et al., 1991; Hasse et al., 1991; Snijders et al., 1993) .
Concentric hypertrophy and reduced cardiac output in the transgenic heart
To examine whether the activated LTK aected cardiac function of the transgenic mice, echocardiographic analyses were performed under anesthetized and unanesthetized conditions. Figure 5a shows blood pressure and heart rate under an unanesthetized a c b Figure 6 Histological and electron microscopic appearances of the transgenic heart and induction of bcl-2 in the transgenic heart. (a) HE-stained transgenic heart showing degeneration of cardiomyocytes (30 weeks of age). Degenerative cardiomyocytes exhibiting homogenous staining patterns are indicated by arrowheads. (b) Electron micrograph of degenerative cardiomyocytes of a transgenic mouse (30 weeks of age). The residual bodies are indicated by asterisks. The boxed area is magni®ed in the inset, showing that the sarcolemmas and membrane-to-membrane contact are well preserved (indicated by arrowheads). Scale bar indicates 1 mm (c) Induction of bcl-2 in the transgenic heart. Proteins extracted from hearts of a transgenic mouse (Tg) and a non-transgenic control (C) (24-30 weeks of age) in lines 3-5, 3-11, and 4-17 were blotted with anti-bcl-2 antibody. Spleens were used as an internal control and proteins extracted from bcl-2-expressing cells (P) and bcl-2-nonexpressing cells (N) were used as positive and negative controls, respectively. The position of bcl-2 is indicated by an arrow and the positions of molecular markers are shown on the left condition. The mean blood pressure of the transgenic mice was signi®cantly lower than that of the nontransgenic littermates and the mean heart rate of the transgenic mice was signi®cantly higher than that of the non-transgenic littermates, suggesting an impaired cardiac function in the transgenic group. The LV function of the transgenic mice was further analysed under an anesthetized condition. The M-mode echocardiography exhibited that the interventricular septum (IVS) and posterior wall (PW) were remarkably thickened and the left ventricular internal dimension (LVID) was markedly reduced in the transgenic heart in comparison to those in the nontransgenic heart (Figure 5b ). The overall results of the echocardiography are summarized in Table 1 . The transgenic heart showed signi®cant increases in interventricular septal thickness (IVST) and posterior wall thickness (PWT) and also showed signi®cant decreases in end-diastolic volume (EDV), end-systolic volume (ESV), and cardiac output (CO). These results demonstrated that the transgenic heart underwent severe concentric hypertrophy, which resulted in reduced cardiac output, low blood pressure and increased heart rate.
Degeneration of cardiomyocytes in the transgenic heart
To investigate the histological abnormalities caused by the LTK transgene product, tissue sections of the transgenic mice and non-transgenic littermates were subjected to pathological analyses. Remarkable and C, control mice; Tg, transgenic mice. IVST, interventricular septal thickness; PWT, posterior wall thickness; EDD, end diastolic dimension; ESD, end systolic dimension; %FS, per cent fractional shortening; EDV, end diastolic volume; ESV, end systolic volume; CO, cardiac output; HR, heart rate. *P50.01 consistent changes were observed in the transgenic heart, where LTK was found to be constitutively activated. As shown in Figure 6a , a number of cardiomyocytes were homogeneously stained by eosin (indicated by arrowheads), which strongly suggests that degenerative changes occurred in the transgenic cardiomyocytes. In addition, in some transgenic animals, cardiomyocytes were focally lost and replaced by calci®cation (data not shown). In other tissues, including brain, thymus, lung, liver, spleen, kidney, and bone marrow, no histological dierences were observed between the transgenic mice and their non-transgenic littermates (data not shown).
To investigate subcellular changes underlying the histological abnormalities in the transgenic heart, electron microscopic analysis was performed. Transgenic cardiomyocytes exhibited a variety of degenerative changes, such as sarcomeric disarray, myo®bril lysis, and pleomorphic mitochondriosis. Figure 6b illustrates degenerative cardiomyocytes, in which there exist a number of residual bodies enveloped by a single membrane and ®lled with a number of heterogeneous electron dense granules and myelin ®gures (indicated by asterisks). In spite of these changes, the sarcolemmas (basement membranes and plasma membranes) of the degenerative cardiomyocytes were well preserved (indicated by arrowheads in the inset of Figure 6b ). These ®ndings strongly suggested that the degenerative changes in the cardiomyocytes were due to apoptosis (Clarke, 1990; Hayashi et al., 1995; James et al., 1993) . We thus investigated whether the expression of bcl-2, a protein preventing apoptosis (Tsujimoto et al., 1984) , might be aected in the transgenic heart. As shown in Figure 6c , the expression level of bcl-2 was found to be upregulated in the transgenic heart in comparison to the non-transgenic heart in all three lines. These results indicated that the transgenic cardiomyocytes underwent degenerative changes closely resembling apoptosis with upregulation of bcl-2.
Reprogramming of gene expression in the transgenic heart
To investigate alteration in gene expression in the transgenic heart, we performed Northern blot analysis of fetal genes, such as atrial natriuretic peptide and skeletal a-actin. As shown in Figure 7 , the expression levels of both genes were strongly upregulated in the transgenic heart, indicating that activated LTK induced reprogramming of gene expression.
Normal development of hematopoietic cells in the transgenic mice
We ®nally examined whether the proliferation and/or dierentiation of the hematopoietic cells might be aected in the transgenic mice, since LTK was originally identi®ed as a protein-tyrosine kinase expressed in hematopoietic tissues (Ben-Neriah and Bauskin, 1988) and was found to be highly expressed in hematopoietic cell lines (Maru et al., 1990) . With this aim, thymic and splenic cells of the transgenic mice and non-transgenic littermates were analysed by¯ow cytometry. Staining of the thymic cells with anti-CD4 and anti-CD8 antibodies showed that most of the thymic cells were double-positive for CD4 and CD8 in both transgenic and non-transgenic thymuses and the ratios of single-positive and double-negative cells were not signi®cantly altered (Figure 8a ). In addition, staining of the splenic cells with anti-Thy1.2, anti-B220, anti-Gr-1, and anti-Mac-1 antibodies exhibited that the percentages of the positively stained cells were similar between transgenic and non-transgenic spleens (Figure 8b ). These results indicated that no obvious developmental abnormalities were observed in the hematopoietic cells in the transgenic mice.
Discussion
Previous studies have demonstrated that the generation of transgenic mice is a powerful tool to investigate the biological properties of receptor-type protein-tyrosine kinases (reviewed in Hanahan, 1988) . To clarify the biological role of LTK, we generated transgenic mice expressing LTK. Previous studies using Northern blotting and immunohistochemical staining have shown that LTK is expressed in thymus, spleen, kidney, liver, hematopoietic cells, placenta, and neural tissues (Ben-Neriah and Bauskin, 1988; Bernards and de la Monte, 1990; Hasse et al., 1991; Maru et al., 1990; Snijders et al., 1993) . To detect a small amount of LTK existing in the tissues, we performed RT ± PCR, a more sensitive method than Northern blotting and immunohistochemical staining. We examined several major organs, including brain, lung, heart, liver, spleen, and kidney, and found that the RT ± PCR product was detected in all the tissues examined (Honda et al., unpublished data) . Although this method cannot estimate the quantitative expression levels of LTK, this result strongly suggests that LTK would play a pivotal role in various kinds of cells. Based on this ®nding, the combination of a cytomegarovirus enhancer and a b-actin promoter was chosen as regulatory elements, since this combination has been reported to allow transgene expression in a wide variety of tissues (Niwa et al., 1991) .
We generated three independent transgenic lines, all of which exhibited remarkable phenotypical, physiological, and pathological changes. We found that the LTK transgene product was expressed in several major organs, as expected from the nature of the promoter (see the upper panels of Figure 3a and b) (Niwa et al., 1991) . However, interestingly, the tyrosine-phosphorylation, kinase activity and multimerization of LTK were detected speci®cally in the heart (see the lower panels in Figure 3a and b, and see also Figure 3c and d). The selective activation of the LTK transgene product in the heart was observed in the embryonic stage as well as in the adult mice (data not shown). When overexpressed, several receptor-type proteintyrosine kinases, such as EGF receptor, have been shown to be dimerized and activated without ligand stimulation (Herren et al., 1993) . In case of the transgenic mice expressing LTK, however, it is obvious that the overexpression of LTK itself did not lead to activation, since in the brain of line 4-17, where the expression of LTK was prevalent as in the heart, no sign of protein activation was detected (Figure 3b ). Thus, there should exist some tissue-speci®c mechanism of activating LTK in the heart. Although we cannot clearly explain the precise mechanism underlying the preferential activation of LTK in the heart, we can consider several possibilities. One possibility is the existence of tissue-speci®c LTK ligand(s). Since previous studies and our results have shown that overexpressed LTK was localized on intracellular membrane, presumably on endoplasmic reticulum (Braskin et al., 1991; Hasse et al., 1991; and Figure  4 ), ligand(s) for LTK might be produced selectively in cardiomyocytes. Another possibility is the tissuespeci®c regulation of LTK. Since LTK has been reported to be activated by redox regulation (Braskin et al., 1991) , it could be postulated that there might exist a similar mechanism of activating LTK in cardiomyocytes.
There remains a question whether the proliferation and/or dierentiation of hematopoietic cells in the transgenic mice might be aected, since LTK was originally identi®ed as a protein-tyrosine kinase expressed in hematopoietic cells (Ben-Neriah and Bauskin, 1988; Maru et al., 1990) . To address this issue, we analysed thymic and splenic cells of transgenic mice and non-transgenic littermates bȳ ow cytometry. We could not detect any obvious dierences in the CD4/CD8 subsets in the thymus and in the expression levels of Thy1.2, B220, Gr-1, and Mac-1 in the spleen (Figure 8a and b) . Moreover, no histological abnormalities were observed in the hematopoietic tissues and no hematological diseases have not been developed in the transgenic mice (data not shown). Thus, the proliferation and dierentiation of hematopoietic cells were not greatly aected in the transgenic mice. The lack of abnormalities in the hematopoietic system might be due to undetectable expression and/or tyrosine-phosphorylation levels of the LTK transgene product in the hematopoietic tissues in the transgenic mice (see Figure 3a and b) .
Physiological studies have revealed that the septum and ventricular wall of the transgenic heart were considerably thickened in comparison to those of the non-transgenic heart (Figure 5b and Table 1 ). These ®ndings indicate that the activated LTK in the heart transduced proliferation signals and induced cardiac hypertrophy as suggested by the in vitro studies using cell lines (Ueno et al., 1995 (Ueno et al., , 1996 . Although there have been several reports describing that the expression of oncogenes such as v-ras and v-fps (Hunter et al., 1995; Yee et al., 1989) , signaling molecules such as gp130 and myf5 (Edwards et al., 1996; Hirota et al., 1995) , or growth factors such as growth hormone and nerve growth factor (Conti et al., 1995; Hassankhani et al., 1995) induced cardiac enlargement, there has been little information concerning the roles of receptor-type protein-tyrosine kinases in cardiac hypertrophy. In this respect, our ®nding would provide insights in the biological roles of receptor-type protein-tyrosine kinases in the mechanisms regulating cardiac development and in the processes leading to cardiac hypertrophy.
Pathological analyses exhibited degeneration of cardiomyocytes in the transgenic heart. Cardiomyocyte degeneration has been noted in mice expressing vfps (Yee et al., 1989) , myf5 (Edwards et al., 1996) , cmyb (Furuta et al., 1993) , or tumor necrosis factor-a (Kubota et al., 1997) . However, in these cases, cardiomyocyte degeneration was accompanied by in®ltration of lymphocytes and macrophages, necrosis of cardiac cells, and cardiac ®brosis (Edwards et al., 1996; Furuta et al., 1993; Kubota et al., 1997) , in contrast that our transgenic heart exhibited no obvious in®ltration of in¯ammatory or immunoreactive cells (Figure 6a) . Therefore, our transgenic mice exhibited a unique case in which the degeneration of cardiomyocytes occurred with no evidence of in¯ammation or immunoreaction. In addition, electron microscopic analyses revealed that the sarcolemmas of the degenerative cardiomyocytes were well preserved and that the degenerated cardiomyocytes still maintained the membrane-membrane contact with viable neighboring cardiomyocytes (Figure 6b ). These pictures are characteristic for apoptotic changes (Clarke, 1990; Hayashi et al., 1995; James et al., 1993) and thus strongly suggest that the activated LTK in the heart induced cardiomyocyte apoptosis as well as cardiomyocyte proliferation. We then examined whether the expression of bcl-2, a factor preventing apoptosis (Tsujimoto et al., 1984) , might be aected in the transgenic heart. Unexpectedly, the expression of bcl-2 was upregulated in the transgenic heart in comparison to non-transgenic heart (Figure 6c ), suggesting a possibility that the expression of bcl-2 was induced to protect cardiomyocytes from activated LTK-induced apoptosis. Since bcl-2 was reported to function as an antioxidant (Hockenbery et al., 1993; Kane et al., 1993) , we compared the activity of lipid peroxidase between the transgenic and non-transgenic hearts.
Since we could not demonstrate any dierence (data not shown), the cardiomyocyte degeneration would be caused by other mechanism(s) than reactive oxygen species.
These physiological and pathological changes in the heart would explain the phenotypical ®ndings observed in the transgenic mice. Retarded growth would be caused by the decreased stroke volume and reduce cardiac output due to concentric hypertrophy. High mortality rate would be caused by the stenosis of left ventricle out¯ow tract and possibly by fatal arrythmia originated from damaged cardiomyocytes.
We also examined the expression of fetal genes, such as atrial natriuretic peptide and skeletal a-actin, which has been reported to be induced in cardiac dysfunction, such as hypertrophic cardiomyopathy (Komuro and Yazaki, 1993) . Our examination demonstrated that the expression of these genes was signi®cantly upregulated in the transgenic heart. It is not clear whether these changes were direct or indirect eects, these results indicated that the activated LTK induced gene reprogramming in the transgenic heart.
Recently, transgenic mice expressing murine LTK under the control of an immunoglobulin promoter/ enhancer were independently generated (Ig/LTK) (Hasse et al., 1995) . In contrast to our case, no obvious phenotypical or pathological changes were reported in Ig/LTK mice (Hasse et al., 1995) . One possibility of this disparity is the dierence in the natures of the promoters used. However, transgene expression was detected in the heart in Ig/LTK mice (Hasse et al., 1995) . Another possibility, which is more likely, is the dierence in the structures of the transgenes. Ig/LTK mice were created using a short form of LTK that encodes a protein without a signal peptide and lacks a glycine-rich stretch just upstream of the transmembrane portion (Hasse et al., 1991) , whereas we used the longest form of LTK that encodes a conventional receptor-type tyrosine kinase with a signal sequence and contains the glycine-rich stretch . Thus, it could be postulated that the N-terminal region and the glycine-rich stretch of LTK might be responsible for the phenotypical and pathological aspects observed in our transgenic mice and that alternatively spliced forms of LTK might contribute to dierent biological properties in vivo.
In this paper, we presented phenotypical, physiological, and pathological changes occurred in transgenic mice expressing LTK. We demonstrated that a certain tissue-speci®c mechanism of activating LTK exists in the heart and showed that the activated LTK in the heart induces cardiac hypertrophy, cardiomyocyte apoptosis, and gene reprogramming. Our ®ndings would provide novel insights into the regulatory mechanism and biological function of LTK in vivo. In addition, this report will contribute to the understanding of the roles of receptor-type protein-tyrosine kinases in the process of cardiac development and cardiac hypertrophy. Moreover, our transgenic mice may ®nd application as an animal model of hypertrophic cardiomyopathy.
Materials and methods

Construction of the transgene and generation of the transgenic mice
A human ltk cDNA which contains the longest open reading frame and encodes a conventional receptor-type tyrosine kinase having a signal sequence and a transmembrane region (referred to as P2 in Toyoshima et al., 1993) was subcloned into a mammalian expression vector pUC-CAGGS, which bears a cytomegarovirus enhancer and a chicken b-actin promoter as regulatory elements. (Niwa et al., 1991) . A Sa1I ± BamHI fragment containing the cytomegarovirus enhancer, the b-actin promoter, the ltk cDNA, and a part of rabbit b-globin gene was excised, puri®ed, and used for microinjection into pronuclei of eggs from C57BL/6XDBA/2 F2 mice (Clea, Japan). Microinjection and embryonal transfer were performed as described previously (Honda et al., 1995) . Transgenic mice were identi®ed by Southern blot analysis of tail DNAs using the injected fragment as a probe as described before (Honda et al., 1995) .
Immunoprecipitation and Western blotting
Proteins were extracted by homogenizing the tissues in Triton lysis buer (1% (v/v) Triton X-100, 150 mM NaC1, 50 mM Tris-C1 (pH 7.4)) with 50 U/ml aprotinin. For detecting the expression or tyrosine-phosphorylation of LTK, 1 mg aliquots of total proteins were incubated with 1 mg anti-LTK monoclonal antibody, 1D31 , and the immunoprecipitated proteins were blotted with 1 mg/ ml of 1D31 or 5 mg/ml of anti-phosphotyrosine monoclonal antibody, 4G10 (Morrison et al., 1990) . For detecting the expression of bcl-2 protein, 100 mg of protein aliquots were blotted with 1 : 100 diluted anti-bcl-2 polyclonal antibody (kindly provided by Dr Y Tsujimoto of Osaka University, Osaka, Japan). Positive signals were visualized using the ProtoBlot Western AP system (Promega).
In vitro kinase assays
One mg aliquots of total proteins were incubated with 1 mg 1D31 coupled to protein A-Sepharose. The immunoprecipitated proteins were washed ®ve times with the lysis buer, followed by ®ve times with the kinase buer (50 mM Tris-C1 (pH 7.4), 10 mM MgC1 2 and 10 mM MnC1 2 ) and incubated with 10 mCi of [ 
Subcellular fractionation
Subcellular fractionation was performed essentially as described elsewhere (Sakai et al., 1994) . In brief, transgenic hearts were homogenized in hypotonic buer (10 mM sodium phosphate, pH 7.0, 5 mM EDTA, and 1 mM DTT) using Dounce homogenizer. After centrifugation at 1000 g, the supernatant was separated into cytosolic and membrane fractions by ultracentrifugation at 50 000 g. Proteins of each fraction were subjected to immunoprecipitation/Western blot analysis.
Histological and electron microscopic examinations
For histological examinations, tissues were ®xed in PBSbuered formalin and processed for staining with hematoxylin and eosin (HE). For electron microscopic examinations, hearts were cut into small cubes and immediately immersed in 4% paraformaldehyde containing 0.25% glutaraldehyde and 4.5% sucrose. The tissue cubes were rinsed in 0.1 M PBS (pH 7.4) containing 4.5% sucrose, ®xed in 1% osmium tetroxide in the same buer, dehydrated by passages through a series of graded ethanols, and embedded in epon. Ultrathin sections were cut with a diamond knife on a LKB (Leica International Headquarters, Gallen, Switzerland) ultramicrotome, mounted on copper grids, stained with uranyl acetate and lead citrate, and examined with a Hitachi H-7000 (Hitachi, Tokyo, Japan) electron microscope.
Immuno¯uorescent staining
Frozen sections of transgenic hearts were stained with 1 : 1000 diluted 1D31 or 1 : 1000 diluted anti-b-Catenin antibody (Sigma) and observed under a confocal microscopic system, MRC1024 (BioRad).
Phenotypical and physiological studies
For growth studies, the body weights of mice were measured every 2 weeks starting at 4 weeks after birth, when they were weaned. To examine ventricular geometry and function in mice, we performed transthoracic M-mode echocardiographic examination. Mice were anesthetized with intraperitoneal treatment of ketamine (10 mg/kg) and xylazine (15 mg/kg). Echocardiography was carried out by using a HP Sonos 100 (Hewlett-Packard Co.) with a 10 MHz imaging transducer. In brief, after obtaining a good-quality two-dimensional image, M-mode image of left ventricle was recorded on paper at 50 mm/s. Measurement of interventricular septal thickness (IVST), left ventricular posterior wall thickness (PWT), and left ventricular internal dimension (LVID) such as end diastolic dimension (EDD) and end systolic dimension (ESD) was performed by use of the leading edge-to-leading edge convention adopted by the American Society of Echocardiography. Per cent fractional shortening (%FS) and cardiac output (CO) were calculated as follows: %FS=((EDD7ESD)/EDD)6100 and CO=SV6HR. Enddiastolic volume (EDV) and end-systolic volume (ESV) were automatically calculated on cardiac ultrasound machine. For monitoring of the hemodynamics, right and/or left carotid arteries were cannulated with stretched PE 50 tubing. The catheters were tunneled under the skin and exteriorized posteriorly at the base of the neck. After complete recovery from anesthesia, arterial blood pressure and heart rate of conscious mice were measured under unrestrained condition and recorded continuously over a period of 60 min by using polygraph system (Nihon Koden Co., Tokyo).
Northern blot analysis
Ten mg aliquots of total RNAs extracted from hearts were subjected to Northern blot analysis as described before (Komuro et al., 1990) using murine atrial natriuretic peptide cDNA (Komuro and Yazaki, 1993) and skeletal a-actin cDNA (Schwartz et al., 1986) as probes.
Flow cytometric analyses
Disaggregated cells prepared from thymuses and spleens of transgenic mice and non-transgenic littermates were stained with FITC-or PE-conjugated commercial monoclonal antibodies, including anti-CD4, anti-CD8, anti-Thy1.2 anti-B220, anti-Gr-1, and anti-Mac-1, according to the manufacturer's instructions. The stained cells were washed three times with PBS and were analysed on a FACS Vantage (Becton Dickinson Mountain View, CA, USA).
